Randomized controlled trial of the Effect of intraVenous iron on Anaemia in Malawian Pregnant women in their third trimester: REVAMP-TT
Effectiveness of intravenous iron administered during the third trimester in Malawian women in the management of anaemia: a 4-year, multicentre, parallel-group, two-arm, open-label randomised controlled superiority trial
Training and Research Unit of Excellence (TRUE), Malawi
590 participants
Nov 24, 2021
Interventional
Conditions
Summary
Antenatal anaemia causes significant risks for both mother and child by amplifying the risks and consequences of serious complications for mothers and their babies. Across Africa, few women receive or take the full recommended course of antenatal oral iron and may present for their initial visit far into the second trimester. We hypothesise that intravenous iron, given as a single rapid infusion of Ferric Carboxymaltose, can assist mothers recovering from anaemia and is superior to the standard of care oral iron tablets.
Eligibility
Inclusion Criteria7
- Confirmed singleton pregnancy in the third trimester (27-35 weeks of gestation, dated by Last Menstrual Period)
- Moderate to severe anaemia not requiring an immediate blood transfusion (Hb <10 g/dl)
- Negative malaria parasitaemia by mRDT
- Currently afebrile with no evidence of septicaemia
- Resident in the study catchment area of Zomba district (Malawi)
- Able to deliver at health facilities within Zomba district (Malawi)
- Written informed consent (including assent if <18 years old)
Exclusion Criteria8
- Previous enrolment in REVAMP trial – ACTRN12618001268235.
- Actively participating in another intervention trial.
- Known hypersensitivity to any of the study drugs.
- Clinical symptoms of malaria or other infection (no fever, no focal symptoms of internal infection i.e. LRTI/ diarrhoea).
- Any condition requiring hospitalisation in the next seven days or serious concomitant illness.
- Known history of sickle cell or sickle-haemoglobin C anaemia.
- Clinically low haemoglobin level requiring a blood transfusion (usually Hb <5g/dl).
- Preeclampsia
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Arm 1: Intravenous Ferric Carboxymaltose (1000 mg for bodyweight > 50 Kg, or 20 mg/Kg for bodyweight < 50 Kg) given once at enrolment as a single infusion over 15 min.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621001239853